Arbogast PG - Search Results

1

COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease.

Ray WA, Stein CM, Daugherty JR, Hall K, Arbogast PG, Griffin MR. Ray WA, et al. Among authors: arbogast pg. Lancet. 2002 Oct 5;360(9339):1071-3. doi: 10.1016/S0140-6736(02)11131-7. Lancet. 2002. PMID: 12383990

2

Underutilization of gastroprotective measures in patients receiving nonsteroidal antiinflammatory drugs.

Smalley W, Stein CM, Arbogast PG, Eisen G, Ray WA, Griffin M. Smalley W, et al. Among authors: arbogast pg. Arthritis Rheum. 2002 Aug;46(8):2195-200. doi: 10.1002/art.10425. Arthritis Rheum. 2002. PMID: 12209525 Free article.

3

High frequency of use of rofecoxib at greater than recommended doses: cause for concern.

Griffin MR, Stein CM, Graham DJ, Daugherty JR, Arbogast PG, Ray WA. Griffin MR, et al. Among authors: arbogast pg. Pharmacoepidemiol Drug Saf. 2004 Jun;13(6):339-43. doi: 10.1002/pds.879. Pharmacoepidemiol Drug Saf. 2004. PMID: 15170762

4

Risk of peptic ulcer hospitalizations in users of NSAIDs with gastroprotective cotherapy versus coxibs.

Ray WA, Chung CP, Stein CM, Smalley WE, Hall K, Arbogast PG, Griffin MR. Ray WA, et al. Among authors: arbogast pg. Gastroenterology. 2007 Sep;133(3):790-8. doi: 10.1053/j.gastro.2007.06.058. Epub 2007 Jul 3. Gastroenterology. 2007. PMID: 17854591

5

Non-aspirin NSAIDs, cyclooxygenase-2 inhibitors and risk for cardiovascular events-stroke, acute myocardial infarction, and death from coronary heart disease.

Roumie CL, Choma NN, Kaltenbach L, Mitchel EF Jr, Arbogast PG, Griffin MR. Roumie CL, et al. Among authors: arbogast pg. Pharmacoepidemiol Drug Saf. 2009 Nov;18(11):1053-63. doi: 10.1002/pds.1820. Pharmacoepidemiol Drug Saf. 2009. PMID: 19637402

6

Cardiovascular risks of nonsteroidal antiinflammatory drugs in patients after hospitalization for serious coronary heart disease.

Ray WA, Varas-Lorenzo C, Chung CP, Castellsague J, Murray KT, Stein CM, Daugherty JR, Arbogast PG, García-Rodríguez LA. Ray WA, et al. Among authors: arbogast pg. Circ Cardiovasc Qual Outcomes. 2009 May;2(3):155-63. doi: 10.1161/CIRCOUTCOMES.108.805689. Epub 2009 May 5. Circ Cardiovasc Qual Outcomes. 2009. PMID: 20031832

7

ADHD drugs and serious cardiovascular events in children and young adults.

Cooper WO, Habel LA, Sox CM, Chan KA, Arbogast PG, Cheetham TC, Murray KT, Quinn VP, Stein CM, Callahan ST, Fireman BH, Fish FA, Kirshner HS, O'Duffy A, Connell FA, Ray WA. Cooper WO, et al. Among authors: arbogast pg. N Engl J Med. 2011 Nov 17;365(20):1896-904. doi: 10.1056/NEJMoa1110212. Epub 2011 Nov 1. N Engl J Med. 2011. PMID: 22043968 Free PMC article.

8

Azithromycin and the risk of cardiovascular death.

Ray WA, Murray KT, Hall K, Arbogast PG, Stein CM. Ray WA, et al. Among authors: arbogast pg. N Engl J Med. 2012 May 17;366(20):1881-90. doi: 10.1056/NEJMoa1003833. N Engl J Med. 2012. PMID: 22591294 Free PMC article.

9

Outpatient adherence to beta-blocker therapy after acute myocardial infarction.

Butler J, Arbogast PG, BeLue R, Daugherty J, Jain MK, Ray WA, Griffin MR. Butler J, et al. Among authors: arbogast pg. J Am Coll Cardiol. 2002 Nov 6;40(9):1589-95. doi: 10.1016/s0735-1097(02)02379-3. J Am Coll Cardiol. 2002. PMID: 12427410 Free article.

10

Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge.

Butler J, Arbogast PG, Daugherty J, Jain MK, Ray WA, Griffin MR. Butler J, et al. Among authors: arbogast pg. J Am Coll Cardiol. 2004 Jun 2;43(11):2036-43. doi: 10.1016/j.jacc.2004.01.041. J Am Coll Cardiol. 2004. PMID: 15172409 Free article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

99 results

Search Page